Compare Ascendis Pharma A/S (ASND) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Omnicom Group Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Omnicom Group Inc. trades at $82 (market cap $23.35B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 3.91% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | OMC | |
|---|---|---|
Market Cap | $17.74B | $23.35B |
Sector | Health | Media |
52-Week High | $277.18 | $85.80 |
52-Week Low | $163.32 | $67.27 |
Enterprise Value | $18.11B | $30.58B |
Dividend Yield | — | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Omnicom Group (OMC) trades at $81.93, up 1.36% on the day, with a bullish technical outlook driven by moving averages and a consensus analyst price target of $105.75. The company reported revenue of $17.27 billion in 2025, though net income was negative $54.5 million, reflecting margin pressure. Recent news highlights major client wins, including IBM and Netflix partnerships, and strong free cash flow generation of $2.94 billion from operations.
OMC presents a value opportunity with a low P/E of 12.16 and positive earnings beats in recent quarters, but faces risks from intense competition and fluctuating profitability. The stock's upside potential is supported by analyst optimism and strategic expansions in AI and streaming advertising, though investors should monitor margin recovery and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
